Opko Health (OPK) Expands Entera Partnership for Drug Co-Development

Opko Health Inc. (NASDAQ:OPK) is one of the best stocks under $3 to invest in. On February 4, Opko Health Inc. (NASDAQ:OPK) announced it expanded its partnership with Entera Bio Ltd., a company developing oral peptide and protein replacement therapies, to advance the first oral long-acting PTH analog (LA-PTH) treatment for patients with hypoparathyroidism, in the form of a once-daily tablet. The two companies have also jointly decided to accelerate development on this medication and expect to file an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) in late 2026.

Under the expanded partnership, Opko Health Inc. (NASDAQ:OPK) and Entera will each hold a 50% pro rata ownership interest in the LA-PTH hypoparathyroidism program. Each company will also be responsible for 50% of the program’s development costs.  The companies maintain their previously announced ownership structure and cost-sharing arrangement for the oral OXM program for metabolic and fibrotic disorders, currently set at 60% for Opko Health Inc. (NASDAQ:OPK) and 40% for Entera.

Opko Health Inc. (NASDAQ:OPK) is a biopharmaceutical and diagnostics company that provides healthcare services. Its operations are divided into the Diagnostics and Pharmaceuticals segments.

While we acknowledge the potential of OPK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 11 Best Stocks Under $3 to Buy Right Now and  10 Most Undervalued Stocks to Buy and Hold for 5 Years

Disclosure: None. This article is originally published at Insider Monkey.